

**Lung Cancer Session Program  
Friday, 21 October 2016 | 13:00 – 18:15  
Al Ras 2**

**13:00 – 14:00 BMS Symposium**

**Session 01:** Early Lung Cancer Session

**Chairpersons:** Aly Abdel Razek, UAE | Aref Chehal, UAE

14:00 – 14:10	Lung Cancer Screening: Abu Dhabi Task Forces	Amgad Elsherif, UAE
14:10 – 14:20	Sleeve Resections	Carlos Mesters, UAE
14:20 – 14:30	Salvage Resections Post Radical Chemo Radiation Therapy	Amgad Elsherif, UAE

**Session 02:**

**Chairpersons:** Falah Al Khatib, UAE | Nadia Malik, UAE | Ali Omar Al Dameh, UAE

14:30 – 14:40	Sub Lobar Resection for T1a Tumors: Is it Time?	Amgad Elsherif, UAE
14:40 – 14:50	Tumor Board Case Discussions	Amgad Elsherif, UAE
14:50 – 15:00	Robotic surgery in Lung cancer – Has it arrived	Sabita Jiwnani, India

**Session 03:**

**Chairpersons:** S. P. Srivastava, India | Pawan Agarwal, India | Nadeem Pervez, UAE

15:00 – 15:10	Adjuvant therapy in Lung cancer in T2 tumors	Nitesh Rohatgi, India
15:10 – 15:25	The Role of Protons in the Treatment of Thoracic Cancers	Karol Sikora, UK
15:25 – 15:35	Neo-Adjuvant Therapy in Localized Lung Cancer	Amit Agarwal, India
15:35 – 15:45	Radiology in Staging of NSCLC	Abhishek Mahajan, India
15:45 – 16:15	<b>Panel Discussion:</b> Early Stage Lung Cancer <b>Moderator:</b> Durgatosh Pandey, India <b>Panelists:</b> Sabita Jijwani, India   Amgad Elsherif, UAE   Karol Sikora, UAE   Nitesh Rohatgi, India   Amit Agarwal, India   Shishir Shetty, India   Abhishek Mahajan, India   Prashant Chajjed, India   Kaltar Das, UAE <b>Chairpersons:</b> Abhijit Sarkar, India   R. P. Baral, India	

- 16:15 – 16:30 **Debate:** Rare mutation are important in EGFR mutation positive Patients  
**Yes:** Arun R. Warriar, India  
**No:** Manish Kumar, India
- 16:30 – 16:45 **Debate:** Is immunotherapy the best second line option in palliative setting in lung cancer patients  
**Yes:** Sajjan Rajpurohit, India  
**No:** Alok Gupta, India
- 16:45 – 17:00 NGS in Lung cancer – How do I do it? Amit Dutt, India
- 17:00 – 17:15 Persistent N2 Disease after. Induction Therapy for Stage IIIA NSCLC: What Next?” Ali Omar Al Dameh, UAE
- 17:00 – 17:45 **Panel Discussion:** Pathology and Molecular Analysis  
**Moderator:** Kumar Prabhash, India  
**Panelists:** Amit Dutt, India | Aaron Hann, UAE | Hassan Youssef Hotait, UAE  
Shilpee Dutt, India | Abhishek Mahajan, India | Kaltar Das, UAE | A Chaudhary, India  
Amit Bhargava, India
- 17:30 – 18:15 **Panel Discussion:** First line treatment options in NSCLC  
**Moderator:** Purvish M. Parikh, India  
**Panelists:** Prashant Parida, India | Kunjahari Medhi, India | Mohit Sharma, India  
Poonam Patil, India | M A Raja, India | Sandeep Agarwal, India | Kaltar Das, UAE  
D. C. Doval, India | Amit Bhargava, India

# Saturday, 22 October 2016 | 09:00 – 13:45

## AI Ras 2

### Session 01: Locally Advanced Lung Cancer

**Chairpersons:** Ramanujam Singarachari, UAE | Ali Omar Al Dameh, UAE  
Aly Abdel Razek, UAE

09:00 – 09:10 Tips for Starting in Minimally Invasive Thoracic Ali Omar Al Dameh, UAE

### Session 02:

**Chairpersons:** Dinesh Sinha, India | Abhishek Kakroo, India

09:10 – 09:20 Management of brain Mets – How do I do it? Shyam Agarwal, UAE

09:20 – 09:35 **Debate:** Expanded Panel of Mutation helps in Patients Management  
**Yes:** Devavrat Arya, India  
**No:** Bharat Chauhan, India

10:35 – 10:50 Debate: Ceritinib Should be considered the First Line Treatment in ALK Positive Patients  
**Yes:** Amol Dongre, India  
**No:** D. C. Doval, India

10:50 – 11:20 **Panel Discussion:** Supportive care in Lung cancer  
**Moderator:** Gautam Goyal, India  
**Panelists:** Mithun Shah, India | Sandip A. Shah, India | Divyesh Kumar, India  
Subhra Kanti Kundu, India | Faraz Khan, UAE | Bharat Chauhan, India  
Norbert W Dreier, UAE | Pawan Agarwal, India

### Session 03:

**Chairpersons:** Ashutosh Gupta, India | Gopal Sharma, India | Khadiga Mohammed, UAE

11:20 – 11:35 **Debate:** Etoposide with Cisplatin in the Best Chemoradiation Protocol in NSCLC  
**Yes:** Padmaj Kulkarni, India  
**No:** Ullas Batra, India

11:35 – 11:50 **Debate:** TKI should be Considered Standard of Care in Adjuvant Setting in EGFR Mutation Positive Patients  
**Yes:** Vibhor Sharma, India  
**No:** Vaibhav Choudhry, India

11:50 – 12:20 **Panel Discussion:** Management of Limited Stage Small Cell Lung Cancer  
**Moderator:** Randeep Singh, India  
**Panelists:** Dominic, India | Amit Dilip Bhatt, India | Shailesh Bondarde, India | Aly Abdel Razek, UAE | Salim Chaib Rassou, UAE | Vaibhav Choudhry, India | Syed Mansoor Hasnain, UAE | Ashutosh Gupta, India

**Session 04:****Chairpersons:** Chandrashekhar V. Pethe, India | Pawan Agarwal, India

12:20 – 12:35 **Debate:** Bevacizumab Should be Considered Standard of Care in Advanced Mesothelioma  
**Yes:** Ankur Bahl, India  
**No:** Shailesh Bondarde, India

12:35 – 12:50 **Debate:** CTRT vs NACT followed by Surgery in N2 Resectable Disease  
**Yes:** Avinash Pandey, India  
**No:** Joydeep Ghosh, India

12:35 – 12:50 Coffee Break

13:00 – 13:15 **Panel Discussion:** Future of advanced Lung cancer management  
**Moderator:** Narayan Prasad, India  
**Panelists:** Falah Al Khatib, UAE | Bharat Chauhan, India  
Chandrashekhar V. Pethe, India | Nadia Malik, UAE | Nadeem Pervez, UAE  
Deni Gupta, India | Padmaj Kulkarni, India

13:15 – 13:30 Bone Mets and its Management Ashish Gulia, India

13:30 – 13:45 Lung Cancer Screening – What are the issues Rajeev Gupta, India